Global pharmaceutical companies have stopped research in Russia: how will this affect the Russians

Kommersant publication with reference to the head of the Center for Mathematical Modeling in development

medicines of the First Moscow StateMedical University named after I.M. Sechenov Kirill Peskov reported that global pharmaceutical companies have curtailed their clinical trials in Russia. Because of this, Russians may lose about 300 drugs. Discuss

The problem is that without officialdocumented studies, drugs cannot be registered. Peskov clarified that, according to statistics, 5-10% of projects end with the launch of the drug on the market, which makes it possible to recoup all investments.

Among the 300 drugs that may disappear from the Russian market, there are those needed for "breakthrough therapy", for the treatment of diseases that are considered incurable.

At the same time, experts believe that the Russianthe pharmaceutical industry will not be able to provide the domestic market with analogues of outdated drugs. The reason is the difficulties with the supply of equipment, reagents and the departure of specialists.